4 picks for the biotech boom in 2011, page-2

Cant beleive your writeup missed CBZ...phase 2 results due in 6 weeks possibly less.
Market for their drug is 20 bill per annum and they are supposed to have the best/safest drug.
Already in discussions with a number of the worlds largest biotech companies.
The board is made up of ceo's presidents vps of some of the worlds largest biotechs like pfizer.

This one will triple or more on the back of good results and going on previous trials they should be good.


Wise owl released a 12 page report with a $1.47 target.

Here are some snippets-

Novo Nordisk option agreement

The result of the current RA phase IIa trial will have profound impact on CBio, which has signed an option agreement with Novo Nordisk. Novo Nordisk is a large Denmark based health care company with a market
capitalization of US$76bn. Novo Nordisk acquired an exclusive option concerning the future development of XToll? in May 2008. If Novo Nordisk exercises its option it is likely that it will gain an exclusive license of
CBio?s IP portfolio.

The agreement provides for upfront payments, and should the option get exercised, any finalised license agreement would include milestone payments and royalties. CBio must first complete the phase IIa trial, results of which are likely to influence Novo Nordisk?s decision. If the
option is exercised the two parties will move into a negotiation period which will not exceed 120 days. During this time CBio is still free to negotiate with other parties. If, after that period, both parties cannot agree
then CBio is free to license with other parties.
An option fee totaling US$3m has been paid to CBio. Milestone payments totaling US$111m have been pre-agreed upon for up to four clinical indications. Any license agreement would also include double digit
royalties on commercial sales of the therapeutic.

XToll? differentiates itself from other RA drugs by not
compromising a person?s immune system.

Phase IIa trial results may confirm the safety and functionality of
XToll?.

Novo Nordisk exercising its option and finalisation of a licensing deal with Novo, or another pharma company, would provide immediate upside for CBio.

XToll? may also be used in other autoimmune diseases such as Psoriasis and Lupus, with further research to follow.

Valuation of $1.47, based on potential milestones and future royalties, suggests upside
Watch this space